Continental Advisors’s AstraZeneca AZN Stock Holding History

Continental Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-2,165	Closed	-$229K	–	83
2020 Q2	$229K	Sell	2,165 -16,451	-88%	-$1.7M	0.12%	80
2020 Q1	$1.66M	Hold	18,616	–	–	1.24%	35
2019 Q4	$1.86M	Sell	18,616 -2,301	-11%	-$217K	0.9%	40
2019 Q3	$1.86M	Hold	20,917	–	–	1.1%	36
2019 Q2	$1.73M	Hold	20,917	–	–	0.97%	43
2019 Q1	$1.69M	Sell	20,917 -18,233	-47%	-$1.44M	0.79%	49
2018 Q4	$2.97M	Hold	39,150	–	–	0.91%	48
2018 Q3	$3.1M	Sell	39,150 -10,000	-20%	-$756K	0.68%	53
2018 Q2	$3.45M	Hold	49,150	–	–	0.86%	49
2018 Q1	$3.44M	Hold	49,150	–	–	0.87%	44
2017 Q4	$3.41M	Sell	49,150 -2,500	-5%	-$169K	0.74%	47
2017 Q3	$3.5M	Buy	51,650 +11,750	+29%	+$742K	0.8%	45
2017 Q2	$2.72M	Hold	39,900	–	–	0.61%	57
2017 Q1	$2.48M	Hold	39,900	–	–	0.56%	56
2016 Q4	$2.18M	Hold	39,900	–	–	0.59%	58
2016 Q3	$2.62M	Sell	39,900 -2,500	-6%	-$163K	0.73%	52
2016 Q2	$2.56M	Buy	42,400 +3,000	+8%	+$174K	0.79%	48
2016 Q1	$2.22M	Hold	39,400	–	–	0.63%	48
2015 Q4	$2.67M	Hold	39,400	–	–	0.68%	49
2015 Q3	$2.51M	Buy	39,400 +2,500	+7%	+$164K	0.67%	53
2015 Q2	$2.35M	Hold	36,900	–	–	0.63%	61
2015 Q1	$2.52M	Sell	36,900 -1,000	-3%	-$69.5K	0.56%	63
2014 Q4	$2.67M	Hold	37,900	–	–	0.54%	59
2014 Q3	$2.71M	Hold	37,900	–	–	0.62%	47
2014 Q2	$2.82M	Sell	37,900 -7,500	-17%	-$542K	0.66%	44
2014 Q1	$2.95M	Buy	45,400 +32,900	+263%	+$2.12M	0.76%	42
2013 Q4	$742K	Hold	12,500	–	–	0.16%	117
2013 Q3	$649K	Sell	12,500 -7,500	-38%	-$377K	0.16%	114
2013 Q2	$946K	Buy	+20,000	New	+$1.02M	0.27%	88

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Continental Advisors's AZN Position: Q3 2020 in Review

Continental Advisors sold out of AstraZeneca (AZN) in Q3 2020, closing a stake of 2,165 shares — an estimated $229K sold.

Continental Advisors first reported a position in AZN in Q2 2013 and held it in 29 quarters. The position peaked at $3.5M in Q3 2017. 723 funds tracked by Wall St. Rank hold AZN as of Q3 2020.

Continental Advisors reported no remaining AstraZeneca position as of Q3 2020 after selling out during the quarter.
Continental Advisors sold 2,165 AstraZeneca shares in Q3 2020, an estimated $229K.
Continental Advisors first reported a position in AstraZeneca in Q2 2013 and held it in 29 quarters.
Continental Advisors's AstraZeneca position peaked at $3.5M in Q3 2017.
723 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2020.

Based on Continental Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.